INS and metabolic syndrome: Furthermore, the recent findings in the population-based Metabolic Syndrome in Men (METSIM) cohort revealed that statin-treated subjects encountered a 46% increased risk of T2D; two mechanisms were principally involved, i.e., decrease in both insulin sensitivity and secretion (10).